

# Pharmaxis Ltd

02:12 26 Mar 2019

## Pharmaxis prepares for advisory committee meeting on use of Bronchitol in the US

Pharmaxis Ltd (ASX:PXS) is preparing for an important meeting that will make recommendations on the possible use of its Bronchitol® product for adult cystic fibrosis patients in the United States.

The company is supporting its licensee Chiesi Group in preparing for a meeting with the Pulmonary-Allergy Drugs Advisory Committee (PADAC) which will take place in May.

Chiesi, which is responsible for the regulatory approval process, has been advised by the US Food and Drug Administration (FDA) that the PADAC meeting will take place in the US on May 8.

### READ: Pharmaxis sees progress in Boehringer Ingelheim's clinical trial in patients with NASH

Pharmaxis is an Australian pharmaceutical research company focused on inflammation and fibrosis. It has a portfolio of products at various stages of development and approval.

One of these products, Bronchitol, for treatment of cystic fibrosis, is marketed in Europe, Russia and Australia and the company is seeking to market it in the large US market.

As part of this process, Chiesi resubmitted the Bronchitol New Drug Application to the FDA in December of 2018.

### Used in treatment of cystic fibrosis patients


Bronchitol is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler.

It works by rehydrating the airway/lung surface and promoting a productive cough. Bronchitol is used for the treatment of cystic fibrosis patients.

**Price:** 0.115

**Market Cap:** \$45.39 m

### 1 Year Share Price Graph



### Share Information

**Code:** PXS

**Listing:** ASX

**52 week High Low**  
**0.305 0.105**

**Sector:** Pharma & Biotech

**Website:** [www.pharmaxis.com.au](http://www.pharmaxis.com.au)

### Company Synopsis:

*Pharmaxis Ltd (ASX:PXS) is a specialty pharmaceutical company focused on the development of new products for the diagnosis and treatment of chronic respiratory and immune disorders.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)



**READ: Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer**

PADAC, which is convened by the FDA, reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of pulmonary disease and diseases with allergic and/or immunologic mechanisms.

Through this process, PADAC makes appropriate recommendations to the Commissioner of Food and Drugs in the US.

The committee comprises a core of 11 voting members including the chair.

These members are selected by the Commissioner from among authorities knowledgeable in the fields of pulmonary medicine, allergy, clinical immunology, and epidemiology or statistics.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

**No investment advice**

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).